Clinical efficacy and safety of nebulized prostacyclin in patients with sARs-CoV-2 (prospective comparative study)-Reference-Cited by-同舟云学术

Clinical efficacy and safety of nebulized prostacyclin in patients with sARs-CoV-2 (prospective comparative study)

Published:2020-08-02 Issue:3 Volume:12 Page:34-41
ISSN:2072-6732
Container-title:Journal Infectology
language:
Short-container-title:test

Author:

Zhdanov K. V.¹,Kozlov K. V.¹,Kas’janenko K. V.¹,Zakharenko S. M.¹,Sukachev V. S.¹,L’vov N. I.¹,Mal’tsev O. V.¹,Lavrenchuk D. V.¹,Lapikov I. I.²,Sharabhanov V. V.¹,Mukhtarov R. M.¹,Bulygin M. A.¹,Potapenko V. G.³,Malikova E. A.¹,Nepomnjashchikh M. N.¹,Mursalov B. B.¹,Sheraliev A. R.⁴,Pervakova M. Yu.⁵,Lapin S. V.⁵

Affiliation:

1. Military Medical Academy named after S.M. Kirov

2. The Promotion of Safe Information Technologies Development Foundtion

3. City Clinical hospital № 31

4. Russian Research Center for Radiology and Surgical Technologies named after academicican A.M. Granov

5. First Saint-Petersburg State Medical University named after academician I.P. Pavlov

Abstract

Aim. In this study we evaluated clinical effectiveness and safety of nebulized prostacyclin in patients with Novel Coronavirus Disease (SARS-CoV-2). Materials and methods: We have included 44 male patients with moderate PCR confirmed SARS-CoV-2 infection in this study. Control group consisted of 23 patients treated with nebulized prostacyclin (PGI2). besides standard therapy. We compared intensiveness and duration of infectious intoxication syndrome, duration of fever, cough as well as SpO2 level, complete blood count and chemokine status values. Results: Statistically significant difference in duration of fever, cough, intensiveness and duration of infectious intoxication syndrome were observed. Lymphocyte and platelet counts were significantly higher in control group We have also noticed significantly lower level of proinflammatory mediators and C4-complement component in control group. Only 1 adverse effect associated with inhaled prostacyclin was reported. Conclusion. Nebulized prostacyclin showed therapeutic efficacy and good safety profile in adults with moderate COVID-19.

Publisher

SPRIDA

Subject

Infectious Diseases

Reference13 articles.

1. Cheng, V. C. Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection / V.C. Cheng, S.K. Lau, P.C. Woo, K.Y. Yuen. – DOI:10.1128/ CMR.00023-07. – Текст: электронный // Clinical Microbiology Reviews. – 2007. – №20(4). – С. 660–694. – URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2176051/ (data obrashhenija 24.06.2020).

2. Lee, N. A Major Outbreak of Severe Acute Respiratory Syndrome in Hong Kong / N. Lee, D. Hui, A. Wu [et. al.]. – DOI: 10.1056/NEJMoa030685. – Текст: электронный // The New England Journal of Medicine. – 2003. – №348. – С. 1986–1994. – URL: https://www.nejm.org/doi/full/10.1056/NEJMoa030685 / (data obrashhenija 24.06.2020).

3. Zaki A.M. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia / A. M. Zaki, S. van Boheemen, T. M. Bestebroer [et. al.]. – DOI: 10.1056/NEJMoa1211721. – Текст: электронный // The New England Journal of Medicine. – 2012. – №367. – С. 1814–1820. – URL: https://www.nejm.org/doi/full/10.1056/NEJMoa1211721 / (data obrashhenija 24.06.2020).

4. de Groot, R.J. Middle East respiratory syndrome coronavirus (MERS-CoV): announcement of the Coronavirus Study Group / R.J. de Groot, S.C. Baker, RS. Baric [et. al.]. – DOI: 10.1128/JVI.01244-13. – Текст: электронный // Journal of virology. – 2013. – №87. – С. 7790 – 7792. – URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3700179/ (data obrashhenija 24.06.2020).

5. Huang, C. Clinical features of patients infected with 2019 novel coronavirus in Wuhan / C. Huang, Y. Wang, X. Li [et. al.]. – DOI: 10.1016/S0140-6736(20)30183-5. – Текст: электронный // The Lancet. – 2020. – №395. – С. 497 – 506. – URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7159299/ (дата обращения 24.06.2020).

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Fighting SARS-CoV-2 infection: experience and prospects;Russian Military Medical Academy Reports;2022-10-19

2. Experience of Military Medicine in the Fight against the New Coronavirus Infection;Herald of the Russian Academy of Sciences;2022-08

3. Results of the work of the Military medical academy research institute of novel coronavirus infection problems through 2020–2021;Bulletin of the Russian Military Medical Academy;2021-12-15

4. Clinical Efficiency and Safety of Riamilovir for Treating Patients with SARS-CoV-2 Infection;Antibiotics and Chemotherapy;2021-02-13